Adjuvant Gemcitabine Plus Cisplatin and Chemoradiation in Patients With Gallbladder Cancer

医学 吉西他滨 胆囊癌 佐剂 顺铂 肿瘤科 内科学 胆囊 癌症 化疗
作者
Vikas Ostwal,Shraddha Patkar,Reena Engineer,Manali Parulekar,Sarika Mandavkar,Prabhat Bhargava,Sujay Srinivas,Rahul Krishnatry,Shivakumar Gudi,Akhil Kapoor,Durgatosh Pandey,Swapnil Patel,Abhishek Singhal,Alok Goel,Tapas Dora,Debashish Chaudhary,Deepali Chaugule,Deepali Naughane,Anuprita Daddi,Rajshree Patil
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:10 (8): 1116-1116 被引量:19
标识
DOI:10.1001/jamaoncol.2024.1944
摘要

Importance: There is limited evidence with regard to the benefit of adjuvant chemotherapy chemoradiotherapy in resected gallbladder cancers (GBCs). Objective: To establish a baseline survival rate for operated GBCs in patients receiving either gemcitabine plus cisplatin (GC) or capecitabine and capecitabine concurrent with chemoradiation (CCRT). Design, Setting, and Participants: The GECCOR-GB study was a multicenter, open-label, randomized phase 2 noncomparator "pick the winner" design trial of adjuvant GC and CCRT in patients with resected histologically confirmed adenocarcinoma or adenosquamous carcinoma of the gallbladder, (stage II/III) with no local residual tumor (R0) or microscopic residual tumor (R1). The study was carried out in 3 tertiary cancer institutions in India. Patients 18 years or older with adequate end-organ functions, and Eastern Cooperative Oncology Group Performance Status of 1 or lower between May 2019 and February 2022 were enrolled. The cutoff date for data analysis was February 28, 2023. Interventions: Patients were randomized 1:1 to receive either GC every 3 weeks (maximum of 6 cycles) or CCRT comprising capecitabine with concurrent chemoradiation (capecitabine concurrent with radiotherapy) sandwiched between capecitabine chemotherapy. Main Outcomes and Measures: The primary outcome was disease-free survival (DFS) at 1 year in randomized patients. This study was conducted as 2 parallel, single-stage phase 2 clinical trials. Within each treatment arm, a 1-year DFS rate of less than 59% was considered as insufficient activity, whereas a 1-year DFS rate of 77% or higher would be considered as sufficient activity. Results: With a median follow-up of 23 months, 90 patients were randomized, 45 in each arm. Overall, there were 31 women (69%) and 14 men (31%) in the GC arm with a mean (range) age of 56 (33-72) years and 34 women (76%) and 11 men (24%) in the CCRT group with a mean (range) age of 55 (26-69) years. In the GC and CCRT arms, 1-year DFS and estimated 2-year DFS was 88.9% (95% CI, 79.5-98.3) and 74.8% (95% CI, 60.4-89.2), and 77.8% (95% CI, 65.4-90.2) and 74.8% (95% CI, 59.9-86.3), respectively. Completion rates for planned treatment was 82% in the GC arm and 62% in the CCRT arm. Conclusions and Relevance: In this randomized clinical trial, GC and CCRT crossed the prespecified trial end points of 1-year DFS in patients with resected stage II/III GBCs. The results set a baseline for a larger phase 3 trial evaluating both regimens in operated GBCs. Trial Registration: ClinicalTrials.gov Identifier: CTRI/2019/05/019323I.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
河不柃完成签到,获得积分10
刚刚
zcywaup发布了新的文献求助30
1秒前
noair完成签到,获得积分10
1秒前
qq完成签到,获得积分10
2秒前
嘻嘻嘻嘻嘻完成签到,获得积分10
3秒前
科研通AI6.2的应助被fighting采纳,获得10
3秒前
FashionBoy的应助被fighting采纳,获得10
4秒前
Sidney完成签到 ,获得积分10
4秒前
4秒前
咎如天发布了新的文献求助10
5秒前
苹果亦巧发布了新的文献求助10
6秒前
橙嘉完成签到 ,获得积分20
6秒前
8秒前
852的应助被Kkk采纳,获得10
8秒前
bkagyin的应助被Kkk采纳,获得10
8秒前
marshyyy完成签到,获得积分10
9秒前
9秒前
大海完成签到,获得积分10
10秒前
12321完成签到,获得积分10
11秒前
天天快乐的应助被Maggie采纳,获得10
11秒前
万能图书馆的应助被Ashin采纳,获得10
13秒前
秋风的应助被123采纳,获得10
13秒前
无花果的应助被zhou采纳,获得10
14秒前
旋123完成签到,获得积分10
14秒前
Maestro_S的应助被wenqing采纳,获得10
14秒前
负责的问雁完成签到,获得积分10
14秒前
咎如天发布了新的文献求助10
14秒前
15秒前
12321发布了新的文献求助30
16秒前
16秒前
baire完成签到,获得积分10
16秒前
16秒前
17秒前
李健的应助被Eli采纳,获得10
17秒前
18秒前
干净夏天完成签到,获得积分20
19秒前
19秒前
20秒前
睡觉了完成签到,获得积分10
21秒前
丁丁当当发布了新的文献求助10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175085
求助须知:如何正确求助?哪些是违规求助? 9566900
关于积分的说明 21788974
捐赠科研通 7769484
什么是DOI,文献DOI怎么找? 3431808
关于科研通互助平台的介绍 2556054
邀请新用户注册赠送积分活动 2477222